WO1995030002A3 - Enhancing the sensitivity of tumor cells to therapies - Google Patents

Enhancing the sensitivity of tumor cells to therapies Download PDF

Info

Publication number
WO1995030002A3
WO1995030002A3 PCT/US1995/005272 US9505272W WO9530002A3 WO 1995030002 A3 WO1995030002 A3 WO 1995030002A3 US 9505272 W US9505272 W US 9505272W WO 9530002 A3 WO9530002 A3 WO 9530002A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor cells
enhancing
therapy
therapies
sensitivity
Prior art date
Application number
PCT/US1995/005272
Other languages
French (fr)
Other versions
WO1995030002A2 (en
Inventor
Ruth A Gjerset
Robert E Sobol
Original Assignee
San Diego Regional Cancer Cent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by San Diego Regional Cancer Cent filed Critical San Diego Regional Cancer Cent
Priority to AU24628/95A priority Critical patent/AU697088B2/en
Priority to EP95918867A priority patent/EP0758382A1/en
Priority to JP7528398A priority patent/JPH09512554A/en
Priority to KR1019960706063A priority patent/KR970702915A/en
Publication of WO1995030002A2 publication Critical patent/WO1995030002A2/en
Publication of WO1995030002A3 publication Critical patent/WO1995030002A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A method for enhancing the effect of a cancer therapy by introducing wild-type therapy sensitizing gene activity into tumor cells having mutant therapy sensitizing gene activity and subjecting the tumor cells to a cancer therapy such as chemotherapy, radiotherapy, biological therapy including immunotherapy, cryotherapy and hyperthermia.
PCT/US1995/005272 1994-04-29 1995-04-28 Enhancing the sensitivity of tumor cells to therapies WO1995030002A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU24628/95A AU697088B2 (en) 1994-04-29 1995-04-28 Enhancing the sensitivity of tumor cells to therapies
EP95918867A EP0758382A1 (en) 1994-04-29 1995-04-28 Enhancing the sensitivity of tumor cells to therapies
JP7528398A JPH09512554A (en) 1994-04-29 1995-04-28 Increased sensitivity of tumor cells to therapy
KR1019960706063A KR970702915A (en) 1994-04-29 1995-04-28 Enhancing The Sensitivity of Tumor Cells to Therapies

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US23622194A 1994-04-29 1994-04-29
US24881494A 1994-05-24 1994-05-24
US33546194A 1994-11-07 1994-11-07
US08/248,814 1994-11-07
US08/335,461 1994-11-07
US08/236,221 1994-11-07

Publications (2)

Publication Number Publication Date
WO1995030002A2 WO1995030002A2 (en) 1995-11-09
WO1995030002A3 true WO1995030002A3 (en) 1995-11-30

Family

ID=27398822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/005272 WO1995030002A2 (en) 1994-04-29 1995-04-28 Enhancing the sensitivity of tumor cells to therapies

Country Status (6)

Country Link
EP (1) EP0758382A1 (en)
JP (2) JPH09512554A (en)
KR (1) KR970702915A (en)
AU (1) AU697088B2 (en)
CA (1) CA2189032A1 (en)
WO (1) WO1995030002A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
EP0575518A1 (en) 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
HUP9901908A3 (en) 1995-07-17 2000-02-28 Univ Texas P16 expression constructs and their application in cancer therapy
KR20080084528A (en) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. Oncolytic vaccinia virus cancer therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510691A1 (en) * 1991-04-26 1992-10-28 Osaka Bioscience Institute DNA coding for human cell surface antigen
WO1993010814A1 (en) * 1991-11-29 1993-06-10 Viagene, Inc. Anti-cancer immunotherapeutic vector constructs
WO1993022443A1 (en) * 1992-04-24 1993-11-11 Sri International In vivo homologous sequence targeting in eukaryotic cells
WO1994006910A1 (en) * 1992-09-18 1994-03-31 Canji, Inc. Gene therapy by retroviral vector with tumor suppressive gene

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510691A1 (en) * 1991-04-26 1992-10-28 Osaka Bioscience Institute DNA coding for human cell surface antigen
WO1993010814A1 (en) * 1991-11-29 1993-06-10 Viagene, Inc. Anti-cancer immunotherapeutic vector constructs
WO1993022443A1 (en) * 1992-04-24 1993-11-11 Sri International In vivo homologous sequence targeting in eukaryotic cells
WO1994006910A1 (en) * 1992-09-18 1994-03-31 Canji, Inc. Gene therapy by retroviral vector with tumor suppressive gene

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CURIEL ET AL.: "High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes", HUMAN GENE THERAPY, vol. 3, pages 147 - 154 *
FAN ET AL.: "Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline", CANCER RES., vol. 55, 15 May 1995 (1995-05-15), pages 1649 - 1654 *
FUJIWARA ET AL.: "Induction of chemosensitivity in human lung cancer cells in-vivo by adenovirus-mediated transfer of the wild-type p53 gene", CANCER RES., vol. 54, 1 May 1994 (1994-05-01), pages 2287 - 2291 *
GJERSET ET AL.: "Dominant effect of transduced wild-type p53 over endogenous mutant p53 in sensitizing tumor cells to therapy", PROC. AM. ASSOC. CANCER RES., vol. 36, 18 March 1995 (1995-03-18) - 22 March 1995 (1995-03-22), pages 21 *
GJERSET ET AL.: "Enhancement of tumor sensitivity to chemotherapy and radiation by wild-type p53 gene transfer", CANCER GENE THER., vol. 1, no. 4, pages 330 *
KUERBITZ ET AL.: "Wild-type p53 is a cell cycle checkpoint determinant following irradiation", PROC. NATL ACAD. SCI., vol. 89, no. 16, 15 August 1992 (1992-08-15), pages 7491 - 7495 *
LOTEM ET AL.: "Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents", BLOOD, vol. 82, no. 4, 15 August 1993 (1993-08-15), pages 1092 - 1096 *
LOWE ET AL.: "p53-dependent apoptosis modulaztes the cytotoxicity of anticancer agents", CELL, vol. 74, 24 September 1993 (1993-09-24), pages 957 - 967 *
MORIMOTO ET AL.: "Overcoming tumor necrosis factor and drug resistance to human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins", CANCER RES., vol. 53, pages 2591 - 2596 *
NOGUCHI ET AL.: "A mouse mutant p53 product recognized by CD4+ and CD8+ T cells", PROC. NATL ACAD. SCI., vol. 91, pages 3171 - 3175 *
PETTY ET AL.: "Expression of the p53 tumor suppressor gene product is a determinant of chemosensitivity", BIOCHEM. BIPHYS. RES. COMMUN., vol. 199, no. 1, 28 February 1994 (1994-02-28), pages 264 - 270 *

Also Published As

Publication number Publication date
EP0758382A1 (en) 1997-02-19
JP2007099780A (en) 2007-04-19
KR970702915A (en) 1997-06-10
AU697088B2 (en) 1998-09-24
CA2189032A1 (en) 1995-11-09
WO1995030002A2 (en) 1995-11-09
JPH09512554A (en) 1997-12-16
AU2462895A (en) 1995-11-29

Similar Documents

Publication Publication Date Title
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2689195A (en) Methods of inducing gene expression by ionizing radiation
WO2001025272A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2000018795A3 (en) Compositions and methods for wt1 specific immunotherapy
MXPA02000192A (en) Compositions and methods for the therapy and diagnosis of lung cancer.
MX9801264A (en) Control of cd44 gene expression for therapeutic use.
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
IE810451L (en) Tumour localization with labeled antibodies
EP0979656A3 (en) Composition containing radioisotopes immobilised on solid particles, and its use in brachytherapy
WO2001024684A3 (en) Methods for treatment of solid tumors and metastasis by gene therapy
WO1999038964A3 (en) Promoter regions of the mouse and human telomerase rna component genes
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
WO1995030002A3 (en) Enhancing the sensitivity of tumor cells to therapies
EP0924296A3 (en) Methods and means for inducing apoptosis by interference in RNA processing
AU5300396A (en) Radiation enhanced gene therapy for treatment of tumors
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO1997016221A3 (en) Genetic induction of receptors for targeted radiotherapy
WO2004009112A8 (en) Use of urease for inhibiting cancer cell growth
EP0716614A4 (en) Treatment of human tumors by genetic transformation of human tumor cells
WO2000067762A3 (en) Selenium-containing pro-drugs for cancer therapy
AU3183089A (en) Improved method for treatment of cancer with activated oncolytic leukocytes
EP0876507A4 (en) Manipulation and detection of protein phosphatase 2c - pp2c alpha- expression in tumor cells for cancer therapy, prevention and detection
AU6617498A (en) Ascorbic acid as an adjuvant in the treatment of malignant tumors using chemo- and radiotherapy
WO2000004153A3 (en) Repression of cell transformation with human pea3

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995918867

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2189032

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1995918867

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1995918867

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995918867

Country of ref document: EP